|Bid||0.00 x 1100|
|Ask||0.00 x 1200|
|Day's Range||299.32 - 306.46|
|52 Week Range||263.30 - 380.76|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||46.82|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On CNBC's "Mad Money Lightning Round," Jim Cramer said Mastercard Inc (NYSE: MA ) is a stock that should be at $300. He believes the CEO did a great job and he wants to buy the stock. Lattice ...
The idea that the majority of the companies you know by name will disappear within a couple of decades is now standard stuff. In this view, our oil companies will soon vanish under climate pressure and ...
Illumina stock crashed in above-average volume on Friday after the genetic testing company reiterated its growth outlook for 2019, implying slower-than-expected fourth-quarter sales.
Stock futures: Amazon plunged on tumbling earnings and weak guidance. Intel signaled a breakout on a surprise earnings gain and bullish outlook. Visa, Illumina and First Solar also reported.
Illumina (ILMN) delivered earnings and revenue surprises of 37.86% and 4.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Illumina on Thursday reported adjusted profit of $1.93 per share on $907 million in sales for its third quarter ended Sept. 30. But consumer genomics trends continue to weigh on the stock.
Investing.com - Illumina (NASDAQ:ILMN) reported third quarter earnings that beat analysts' expectations on Thursday and revenue that topped forecasts.
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For more than a decade now genomic medicine has been revolutionizing the way we diagnose and treat disease. Illumina (ILMN) has been at the forefront of that revolution, notes growth stock expert Ian Wyatt, editor of Million Dollar Portfolio.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Qiagen NV (NYSE: QGEN) shares were coming under intense selling pressure Tuesday following a trio of announcements from the company. The German molecular and genetic testing company announced preliminary third-quarter results and said it expects net sales growth of 3% at constant exchange rates, lower than its previous outlook for 4-5% CER growth. Qiagen attributed the weakness to significantly weaker-than-expected developments in China.